We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Nanopore Technologies Plc | LSE:ONT | London | Ordinary Share | GB00BP6S8Z30 | ORD GBP0.0001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 0.32% | 154.70 | 154.30 | 155.10 | 155.60 | 154.20 | 155.50 | 689,673 | 08:26:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 169.67M | -154.51M | -0.1641 | -9.40 | 1.45B |
Date | Subject | Author | Discuss |
---|---|---|---|
26/6/2024 07:07 | Almost half of Mcap is Cash. This drop is over done Price target £1.60 and some even higher. On Monday, Barclays (LON:BARC) adjusted its price target on shares of Oxford Nanopore Technologies (ONT:LN) (OTC: ONTTF), reducing it to GBP1.60 from GBP1.85, while maintaining an Overweight rating on the stock. The revision reflects the firm's outlook for the company in light of recent market conditions and operational strategies. The company faced challenges in the last two quarters, which have been a period of assessment for many firms in the sector. Despite these hurdles, Barclays anticipates some sequential improvements in Oxford Nanopore's end markets. Oxford Nanopore's revenue composition is expected to be more heavily weighted towards the second half of the year. This projection is supported by several factors including new product launches, increased utilization of the company's offerings, and the timing of larger projects that are in the pipeline. The firm highlights Oxford Nanopore's capital expenditure-light business model as a distinctive advantage. This approach could potentially set the company apart from competitors in the biotechnology and genomics industry, which often require significant upfront investments. In summary, while the price target has been lowered, the Overweight rating suggests that Barclays continues to see Oxford Nanopore as a favorable investment, with positive developments anticipated in the latter half of the year. | seball | |
26/6/2024 06:56 | There is no sign of things letting up if you even track just the last month - PACB being hurt equally atm. I cannot see any way to pick a specific share price just yet with any sense of certainty and think the rot share price drop wise will stop at this point. | takeiteasy | |
26/6/2024 06:44 | Across the board. | p1nkfish | |
26/6/2024 05:13 | I suggest that ONT must regret ever listing on such a dysfunctional UK stock exchange - yes agreed. But the other two are US listed so maybe a wider sector derating is going on atm? | takeiteasy | |
24/6/2024 19:54 | Yes technicals can be all important.Take Bitcoin.Strip away all the waffle about blockchain and in reality the movement of bitcoin is no more than a function of the weight of buyers and sellers and that is what chartism monitors.In the absence of meaningful functional research,the technicals are paramount.Looking at the ONT chart who can meaningfully predict the bottom with past apparent support levels being breached again and again.I suppose at some juncture,they’ | steeplejack | |
24/6/2024 17:49 | Was always on the cards when 90p went. Now a question of how low, before it recovers. Yes, I'm afraid technicals are important. | brucie5 | |
24/6/2024 16:15 | Well,luckily i have just put a very small toe in the water here but frankly,i can’t be bothered to make head or tail of this price collapse and buy more until there’s greater clarity.Looks like this is moved by technical analysis rather than fundamentals.The management who bought stock back in early March around 127p must be a wee bit bemused. i’m increasingly reluctant to buy UK stocks nowadays in any meaningful size and frankly wouldn’t bother at all if i wasn’t domiciled in the UK …..and born here…old habits die hard. | steeplejack | |
24/6/2024 13:27 | This is going to bounce as oversold, buyers will start to out number sellers. over £400m in cash. Those able to hold for the next few months on run up to October will be handsomely rewarded imo. Good luck all | seball | |
24/6/2024 09:45 | Indeed. But I tend to think the second test of the 90 threshold is more telling.Last time it was in the 90s I bought quite heavily on hunch of likely support and sold in the 100s when momentum evaporated. | brucie5 | |
24/6/2024 08:31 | I wouldn't read too much into the price movements of an esoteric second liner like ONT.the UK market remains in a malaise and the analytical coverage of companies like Oxford Nanophore remains anaemic.Namesake Oxford Biomedica provides a reasonable template i suspect.Slumping as low as 170p a few months back,the stock has now recovered to around 320p.As we move into the Autumn,bid speculation should see the stock begin to recover but for now its disinterest rather than insight that is depressing this stock. | steeplejack | |
24/6/2024 07:52 | Retesting historic support for the second time. Odd perhaps given imminent aforementioned discussion of LAT shares? | brucie5 | |
24/6/2024 07:08 | An Analytical Eye on mRNA How a new collaboration looks to improve analytical testing for mRNA products | bamboo2 | |
21/6/2024 13:01 | Thank you for doing that bamboo2, good to have it confirmed. Now hoping for good news in the update next month. | dawneyd | |
21/6/2024 06:42 | dawneyd, I searched again, then finally wrote to the co. It's 5th October. Thanks for prompting this conversation. I will amend the header. | bamboo2 | |
20/6/2024 08:17 | dawneyd, thanks. I do get your 'no date' interpretation as well. What leaves me thinking issue date for LAT's is 22/6/21 is the fact that I have searched everywhere for an alternate issue date, but have not found anything yet! | bamboo2 | |
20/6/2024 07:55 | bamboo2 - I know you were trying to get discussion on this early, which is good as it maybe wasn't clear. I still think your reading that para on p178 wrong, the semi-colon after 'company' separates (a) from (b), and the LAT are not part of the equity award. The 'shareholders approved:' both of those things separately is my reading, so the 22 June date is only the equity award issue ('grant') and no date given for the LAT. I'm sticking with October in my thinking as it was dependent on the IPO happening (hehe - unless the company issue RNS Monday saying I'm wrong and there just been cancelled :) | dawneyd | |
20/6/2024 07:28 | Price, currently, doesn't signal any imminent change? | p1nkfish | |
20/6/2024 06:40 | dawneyd, as you can see from earlier posts, I have been open about the ambiguity in the registration document, and have tried to get others to look into what they think might be the actual date of their expiry. If you want a definitive answer, it's probably simpler to email IR at the co, as I would guess that this info will be freely available. ==================== Quote, use p 178 for full text "On 9 June 2021, the shareholders approved: (a) a conditional retention equity award ... ... On 22 June 2021, awards under this plan were granted to the executive directors of the company; and (b) a limited anti-takeover non-voting share of £1.00 in the capital of the Company (a “LAT Share”)." ==================== Then read on further, "The rights attributable to a LAT Share will cease (and that LAT Share will be capable of being repurchased or cancelled by the Company) on the earlier of: (a) the date falling three years after the date of the issue of that LAT Share;..."etc | bamboo2 | |
19/6/2024 20:53 | bamboo2 - going back to your December post with page number that 22 June date looks for point (a) there only, no? For the 'conditional retention equity award'? It has 'On 22 June 2021, awards under this plan were granted to the executive directors of the company; and' Then its point (b) after that for the LAT, with no date. I always thought October flotation for the expiry start, which you also mentioned in that post. | dawneyd | |
19/6/2024 20:34 | seball - thanks for confirming that, I had already guessed from the format it was likely. It's also given you complete nonsense! Please, everyone, if you are going to use an AI/chatbot rather than reading the RNS and docs yourself then you have to state a) which robot you used, b) the exact question you gave it, and then c) post the answer. That way everyone else can see the result in the right context and then check it themselves. You can't just post up a "quote" and not make that clear. Cheers. -/end rant ;) | dawneyd | |
19/6/2024 18:48 | Hi it was what came out of chat gpt. Thanks | seball | |
19/6/2024 16:26 | bamboo2 - I already know whats in this thread, and I know what 'LAT' means for ONT. My specific question to seball still stands as the post doesnt make sense. | dawneyd | |
19/6/2024 16:07 | The LAT shares and their unintended consequences were discussed earlier in the thread. The header refers to the ambiguity of expiry dates. The flotation paperwork clearly states three years from issue, however it is the issue date that is/has been unclear. Clive Brown gave up his LAT share when he declined re-election to the BOD earlier this year. dawneyd, type LAT into the 'search thread' box at the top of the header. | bamboo2 | |
19/6/2024 15:44 | seball - what are "Limited Availability Tranche" shares, never heard that before? And is the second part of the post with the dates jist you paraphrasing from an AGM notice, or did you get all of it from an AI/chatbot request? Any links please? | dawneyd |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions